Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전대원 | - |
dc.date.accessioned | 2019-12-10T20:19:13Z | - |
dc.date.available | 2019-12-10T20:19:13Z | - |
dc.date.issued | 2018-12 | - |
dc.identifier.citation | CHINESE MEDICAL JOURNAL, v. 131, no. 14, page. 1645-1651 | en_US |
dc.identifier.issn | 0366-6999 | - |
dc.identifier.uri | https://insights.ovid.com/crossref?an=00029330-201807200-00002 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/121160 | - |
dc.description.abstract | Background: Until now, various types of combined therapy with nucleotide analogs and pegylated interferon (Peg-INF) in patients with hepatitis B patients have been tried. However, studies regarding the benefits of de novo combination, late-add on, and sequential treatment are very limited. The objective of the current study was to identify the efficacy of sequential treatment of Peg-INF after short-term antiviral treatment.Methods: Between June 2010 and June 2015, hepatitis B e antigen (HBeAg)-positive patients (n = 162) received Peg-IFN for 48 weeks (mono-treatment group, n = 81) and entecavir (ETV) for 12 weeks with a 48-week course of Peg-IFN starting at week 5 of ETV therapy (sequential treatment group, n = 81). The primary endpoint was HBeAg seroconversion at the end of follow-up period after the 24-week treatment. The primary endpoint was analyzed using Chi-square test, Fisher's exact test, and regression analysis.Results: HBeAg seroconversion rate (18.2% vs. 18.2%, t = 0.03, P = 1.000) and seroclearance rate (19.7% vs. 19.7%, t = 0.03, P = 1.000) were same in both mono-treatment and sequential treatment groups. The rate of alanine aminotransferase (ALT) normalization (45.5% vs. 54.5%, t = 1.12, P = 0.296) and serum hepatitis B virus (HBV)-DNA <2000 U/L (28.8% vs. 28.8%, t = 0.10, P = 1.000) was not different in sequential and mono-treatment groups at 24 weeks of Peg-INF. Viral response rate (HBeAg seroconversion and serum HBV-DNA <2000 U/L) was not different in the two groups (12.1% vs. 16.7%, t = 1.83, P = 0.457). Baseline HBV-DNA level (7 log(10)U/ml vs. 7.5 log(10)U/ml, t = 1.70, P = 0.019) and hepatitis B surface antigen titer (3.6 log(10)U/ml vs. 4.0 log(10)U/ml, t = 2.19, P = 0.020) were lower and predictors of responder in mono-treatment and sequential treatment groups, respectively. Conclusions: The current study shows no differences in HBeAg seroconversion rate, ALT normalization, and HBV-DNA levels between mono-therapy and sequential therapy regimens. | en_US |
dc.description.sponsorship | This study was supported by a grant from Roche. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | WOLTERS KLUWER MEDKNOW PUBLICATIONS | en_US |
dc.subject | Entecavir | en_US |
dc.subject | Hepatitis B | en_US |
dc.subject | Peginterferon Alfa-2a | en_US |
dc.title | Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatits B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study) | en_US |
dc.type | Article | en_US |
dc.relation.no | 14 | - |
dc.relation.volume | 131 | - |
dc.identifier.doi | 10.4103/0366-6999.235880 | - |
dc.relation.page | 1645-1651 | - |
dc.relation.journal | CHINESE MEDICAL JOURNAL | - |
dc.contributor.googleauthor | Jun, Dae Won | - |
dc.contributor.googleauthor | Ahn, Sang Bong | - |
dc.contributor.googleauthor | Kim, Tae Yeob | - |
dc.contributor.googleauthor | Sohn, Joo Hyun | - |
dc.contributor.googleauthor | Kim, Sang Gyune | - |
dc.contributor.googleauthor | Lee, Se Whan | - |
dc.contributor.googleauthor | Kim, Byung Ho | - |
dc.contributor.googleauthor | Kim, Dong Joon | - |
dc.contributor.googleauthor | Kim, Ja Kyung | - |
dc.contributor.googleauthor | Kim, Hyoung Su | - |
dc.relation.code | 2018001751 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | noshin | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.